|
|||||
|
|
|
|
|
|
 |
|
 |
|
|
|||||||||||
| Track 1 | AVOREN: Interferon- 2a with or without bevacizumab as first-line therapy in mRCC |
 |
|||||||||
| Track 2 | Use of bevacizumab monotherapy in RCC | |
|||||||||
| Track 3 | Bevacizumab-associated side effects and toxicity | |
|||||||||
| Track 4 | Potential antitumor mechanism(s) of bevacizumab | |
|||||||||
| Track 5 | Treatment algorithm for patients with mRCC |
|
|||||||||
| Track 6 | Incorporation of bevacizumab into the management of mRCC | |
|||||||||
| Track 7 | ECOG-E2805: Adjuvant sunitinib, sorafenib or placebo in resected RCC | |
|||||||||
| Track 8 | Use of the mTOR inhibitor temsirolimus in patients with poor-risk RCC | |
|||||||||
| Track 9 | Increasing doses of sunitinib or sorafenib in clinical practice | |
|||||||||
| Track 10 | The Randomized Discontinuation clinical trial design | |
|||||||||
| Track 11 | Studying combinations of molecularly targeted agents in RCC | |
|||||||||
| Track 12 | Management of VEGF TKI-associated toxicities | |
|||||||||
| Track 13 | Use of combined therapy in RCC | |
|||||||||
| Track 14 | Targeting novel pathways in RCC | |
|||||||||
|
|||||||||||
| Track 1 | SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinaseS) Clinic | |
|||||||||
| Track 2 | Hand-foot skin reactions and anticancer therapy | |
|||||||||
| Track 3 | Case report of hand-foot and stump syndrome associated with sorafenib | |
|||||||||
| Track 4 | Time course and management of hand-foot syndrome associated with sorafenib and sunitinib | |
|||||||||
| Track 5 | Prophylaxis of hand-foot syndrome associated with sorafenib and sunitinib | |
|||||||||
| Track 6 | Additional dermatologic toxicities associated with sorafenib and sunitinib |
|
|||||||||
| Track 7 | Alopecia associated with sorafenib and sunitinib | |
|||||||||
| Track 8 | Topical agents for treating dermatologic reactions associated with sorafenib and sunitinib | |
|||||||||
| Track 9 | Quality-of-life issues associated with hand-foot skin reactions | |
|||||||||
| Track 10 | Dermatologic toxicities associated with interferon | |
|||||||||
| Track 11 | Dermatologic toxicities associated with EGFR inhibitors | |
|||||||||
| Track 12 | Implications of dermatologic side effects for the use of agents in the adjuvant setting | |
|||||||||
| Track 13 | Algorithm for the management of EGFR-related dermatologic toxicities | |
|||||||||
| Track 14 | Mechanism of EGFR-related dermatologic toxicity | |
|||||||||
| Track 15 | Correlation between skin reactions and response to EGFR inhibitors | |
|||||||||
| Track 16 | Frequently asked questions about dermatologic reactions | |
|||||||||
| Track 17 | Counseling patients about dermatologic toxicities | |
|||||||||
| Track 18 | Development of a specialty interest in dermatologic toxicities of cancer treatments | |
|||||||||
| Track 19 | Dermatologic toxicities associated with pegylated doxorubicin and docetaxel | |
|||||||||
|
|||||||||||
| Track 1 | Background and design of AVOREN: Phase III trial of interferon-2a
with or without bevacizumab as first-line therapy in mRCC |
|
|||||||||
| Track 2 | AVOREN trial: Duration of therapy and incidence of side effects | |
|||||||||
| Track 3 | Clinical use of bevacizumab in patients with mRCC | |
|||||||||
| Track 4 | Clinical trial strategies incorporating TKIs with bevacizumab in RCC | |
|||||||||
| Track 5 | Clinical use of temsirolimus or sorafenib in patients with mRCC | |
|||||||||
| Track 6 | TARGET trial of sorafenib as second-line therapy for patients with RCC |
|
|||||||||
| Track 7 | Emerging Phase II data with sorafenib in RCC | |
|||||||||
| Track 8 | Treatment algorithm for patients with mRCC | |
|||||||||
| Track 9 | Discussion of an adjuvant bevacizumab trial in RCC | |
|||||||||
| Track 10 | Side effects associated with sorafenib and sunitinib | |
|||||||||
 |
Terms of Use/Disclaimer | Privacy Policy | Hardware/Software Requirements Copyright © 2007 Research To Practice. All Rights Reserved. |
 |
